Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 May 2022 | Story Lunga Luthuli | Photo Supplied
Melissa De Aveiro

Singer, writer, and motivational speaker, Melissa de Aveiro, says: “One can only rise from the ashes when the fire starts again, and the beauty of it all is that the ashes is stuck to your clothes. As you move on, you build off it as it falls from your clothes.”

She said: “When the fire starts in you, nothing is going to stop it.”

This she said at the Division of Organisational Development and Employee Well-being’s Rising from the Ashes event held at the Centenary Complex on the Bloemfontein Campus. Melissa’s story is about never giving up and “never backing down – even when people throw you with rocks, use the rocks to build a new road”.

Melissa said: “Many people unfortunately do not rise from the ashes because there is no support from friends, people. You can never do it alone as the journey through the ashes is lonely.”

Melissa believes to get through the ashes, one has to go back and “remind yourself of when it was good in your life, remind yourself about the positive things – even though things might not be great now”.

Known as the 'Weskus Dutchess', and growing up in Vredendal, Western Cape, Melissa’s tough life, sexual abuse, drug abuse, homelessness, and the death of her son never stopped her from dreaming. All the setbacks planted in her a “passion for a guitar and people, a birth of a new season, a desire to change the world”.

To rise from the ashes, Melissa said, “You need to go back to the place where you were hurting, confront the demons, the people that abused you, maybe forgive them and remove the chains you are tied with.”

Susan van Jaarsveld, Senior Director: Human Resources at the University of the Free State, believes that hosting wellness events is a way for the UFS to show that “employees are the most valuable asset of the university and need to be looked after”.

Susan said: “Staff need to know that it is okay not to be okay. However, the UFS has systems to look after your well-being. People need to know that they are not alone, they can make use of the Department of Human Resources’ Careways Employee Wellness Programme.”

Susan believes it was important to host the event, as “staff need face-to-face interaction for their well-being, it helps people to know they are not alone”.

Melissa, the author of the book Weskus Wonderwerk, believes in being unstoppable. She said: “To rise from the trenches, always think positive about yourself, you must exist. You cannot give up; your worth cannot be determined by an individual.” 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept